インスリン・デリバリーシステムの市場分析(2007-2010年）

The research report “Insulin Delivery Systems Market Analysis (2007-2010)” by RNCOS gives an exhaustive analysis on the global insulin market and various Insulin delivery methods. The report investigates the market for various devices used for delivering insulin, including syringes, pens, pumps, needle-free injectors and inhalers. It also takes into account pros and cons of each device and gives a detailed analysis on their future prospects.

The insulin market, driven by the increasing prevalence of diabetes, is presently witnessing robust double-digit growth, thus pushing strong demand for insulin delivery devices. Most of the insulin today is available in injectable form through syringes, pens, pumps and needle-free devices, however, the pain and inconvenience of most of these devices are driving pharmaceutical companies to discover other ‘painless' modes of insulin delivery, particularly oral methods.

In the search for introducing painless devices, Exubera, the first inhalable insulin, was launched by Pfizer in 2006. However, the device failed to create any major impact and received only a fraction of prescriptions before the company finally decided to stop selling it in 2007. A similar fate is expected for other inhalable insulin. Nevertheless, the market for insulin continues to be immensely lucrative with around 380 Million people having diabetes by 2025, driving drug companies to continue to eye this market which will always be a good bet.

• The insulin market is expected to witness double-digit growth during 2007-2012.
• By 2025, nearly one-third of total diabetes patients will be from India and China and both have relatively nascent but emerging insulin markets.
• Insulin syringes and pumps dominate the US market.
• Majority of users in Europe and Japan continue to use pen devices.
• Needle-free injectors have been launched in the market decades ago, but so far, have failed to create a major impact.
• Exubera, the first inhalable insulin, which was earlier thought to be a billion dollar blockbuster, turned out to be one of the biggest flops in pharmaceutical history.

• Evaluation of past, current and future market trends
• Discussion about the modes of insulin delivery
• A detailed analysis of the major insulin delivery devices
• Analysis of pros and cons of major insulin devices
• Scope of the major insulin delivery systems all over the world
• Analysis of various challenges and opportunities for the industry
• Profile discussion of key players in the sector

This section provides the overview, key facts and financial information of prominent players in the global insulin delivery market like Eli Lilly & Company, Novo Nordisk A/S, Sanofi-Aventis, Becton Dickinson & Company and Medtronic Inc.

Information has been sourced from various sources like books, newspapers, trade journals, and white papers, industry portals, government agencies, trade associations, monitoring industry news and developments, and through access to more than 3000 paid databases.

The analysis methods include ratio analysis, historical trend analysis, linear regression analysis using software tools, judgmental forecasting, and cause and effect analysis.

1. Analyst View

2. Diabetes Disease Indicator

3. Diabetes & Obesity

4. Global Market Analysis

• 4.1 Global Diabetes Drugs Market
• 4.2 Global Insulin Market
  • 4.2.1 India
    • 4.2.1.1 Prevalence
    • 4.2.1.2 Market Analysis
  • 4.2.2 China
    • 4.2.2.1 Prevalence
    • 4.2.2.2 Market Analysis
  • 4.2.3 US
    • 4.2.3.1 Prevalence
    • 4.2.3.2 Market Analysis
  • 4.2.4 Russia
    • 4.2.4.1 Prevalence
    • 4.2.4.2 Market Analysis
  • 4.2.5 Japan
    • 4.2.5.1 Prevalence
    • 4.2.5.2 Market A+G1nalysis
  • 4.2.6 Germany
    • 4.2.6.1 Prevalence
    • 4.2.6.2 Market Analysis
  • 4.2.7 Pakistan
    • 4.2.7.1 Prevalence
    • 4.2.7.2 Market Analysis
  • 4.2.8 Brazil
    • 4.2.8.1 Prevalence
    • 4.2.8.2 Market Analysis
  • 4.2.9 Mexico
    • 4.2.9.1 Prevalence
  • 4.2.10 Egypt
    • 4.2.10.1 Prevalence

5. Insulin Delivery Devices

• 5.1 Present Devices
  • 5.1.1 Insulin Pens
    • 5.1.1.1 Mechanism & Technologies
    • 5.1.1.2 Market Analysis
      • 5.1.1.2.1 Global
      • 5.1.1.2.2 US
      • 5.1.1.2.3 Europe
      • 5.1.1.2.4 Japan
    • 5.1.1.3 Pros & Cons
    • 5.1.1.4 Key Players
  • 5.1.2 Insulin Pumps
    • 5.1.2.1 Mechanism & Technologies
    • 5.1.2.2 Market Analysis
      • 5.1.2.2.1 Global
      • 5.1.2.2.2 US
      • 5.1.2.2.3 Non US
    • 5.1.2.3 Pros & Cons
    • 5.1.2.4 Key Players
  • 5.1.3 Inhaled Insulin
    • 5.1.3.1 Mechanism & Technologies
    • 5.1.3.2 Market Analysis
      • 5.1.3.2.1 Exubera Lackluster Performance
      • 5.1.3.2.2 Why Exubera Failed?
        • 5.1.3.2.2.1 Poor Preparation for Product Launching
        • 5.1.3.2.2.2 Insurance Reimbursements
        • 5.1.3.2.2.3 Lack of Market Understanding for this Product
        • 5.1.3.2.2.4 Effectiveness of Other Diabetes Treatments
        • 5.1.3.2.2.5 Lack of Safety Data & Health-related Problems
        • 5.1.3.2.2.6 Poor Design & Other Inconveniences
    • 5.1.3.3 Pros & Cons
    • 5.1.3.4 Projections & Future of Other Inhalable Insulin
  • 5.1.4 Insulin Syringes
    • 5.1.4.1 Mechanism & Technology
    • 5.1.4.2 Market Analysis
    • 5.1.4.3 Pros & Cons
    • 5.1.4.4 Future Outlook (2007-2010)
  • 5.1.5 Insulin Jet Injectors
    • 5.1.5.1 Mechanism & Technologies
    • 5.1.5.2 Market Analysis
    • 5.1.5.3 Pros & Cons
    • 5.1.5.4 Future Outlook (2007-2010)
• 5.2 Future Devices
  • 5.2.1 Oral Insulin
  • 5.2.2 Insulin Patch
  • 5.2.3 Implantable Insulin Pumps

6. Industry Analysis

• 6.1 Drivers
  • 6.1.1 Increasing Number of Diabetic Patients
  • 6.1.2 Convenient & Less Painful Modes of Insulin Delivery
  • 6.1.3 Improved Access & Lower Insulin Prices in the Developing World
  • 6.1.4 Early Diagnosis & Increasing Awareness for Treatment
  • 6.1.5 Government Support
• 6.2 Challenges
  • 6.2.1 High R&D & Production Cost
  • 6.2.2 Long Time to Market
  • 6.2.3 Poverty
  • 6.2.4 Insurance Reimbursement
  • 6.2.5 Traditional Treatments
  • 6.2.6 High Cost of Insulin Inhalers
  • 6.2.7 Rapidly Changing Technology
• 6.3 Opportunities
  • 6.3.1 US & Developing Countries - Potential Markets for Insulin Syringes
  • 6.3.2 Europe & Japan - Potential Markets for Pen Devices
  • 6.3.3 Developed World - Potential Market Oral Insulin
  • 6.3.4 US - Potential Market for Insulin Pumps

7. Future Outlook

• 7.1 Global Diabetes Drug Market (2007-2012)

8. Key Players

• 8.1 Eli Lilly & Company
• 8.2 Novo Nordisk A/S
• 8.3 Sanofi-Aventis
• 8.4 Becton, Dickinson and Company
• 8.5 Medtronic, Inc.

• Figure 3-1: Global - Overweight & Obese Population (in Billion), 2005, 2007E & 2015E
• Figure 4-1: Global - Number of Diabetic Patients (in Million), 2003 & 2007
• Figure 4-2: Global - Diabetes Drugs Market (in Billion US$), 2004-2006
• Figure 4-3: Global - Insulin Market (in Billion US$), 2005 & 2006
• Figure 4-4: India - Diabetic Patients in Age Group 20-79 Years (in ' 000), 2003-2006E
• Figure 4-5: India - Forecast for Diabetic Patients in Age Group 20-79 Years (in ' 000), 2007, 2013, 2019 & 2025
• Figure 4-6: India - Insulin Market (in Billion INR), 2003 & 2006
• Figure 4-7: India - Share of Key Players in Insulin Market (%), 2004
• Figure 4-8: China - Diabetic Patients in Age Group 20-79 Years (in ' 000), 2003-2006E
• Figure 4-9: China - Forecast for Diabetic Patients in Age Group 20-79 Years (in ' 000), 2007, 2013, 2019 & 2025
• Figure 4-10: China - Insulin Market (in Billion RMB), 2005, 2006E & 2012F
• Figure 4-11: China - Share of Key Players in Insulin Market (%), 2004*
• Figure 4-12: US - Diabetic Patients in Age Group 20-79 Years (in ‘000), 2003-2006E
• Figure 4-13: US - Forecast for Diabetic Patients in Age Group 20-79 Years (in ' 000), 2007, 2013, 2019 & 2025
• Figure 4-14: US - Insulin Market (in Billion US$), 2003-2006E
• Figure 4-15: US - Share of Key Players in Insulin Market (%), 2006
• Figure 4-16: Russia - Diabetic Patients in Age Group 20-79 Years (in ' 000), 2003-2006E
• Figure 4-17: Russia - Forecast for Diabetic Patients in Age Group 20-79 Years (in ' 000), 2007, 2013, 2019 & 2025
• Figure 4-18: Russia - Insulin Market (in Million US$), 2005-2008E
• Figure 4-19: Russia - Share of Key Players in Insulin Market (%), 2005
• Figure 4-20: Russia - Share of Sales Channel in Insulin Market (%), 2005
• Figure 4-21: Japan - Diabetic Patients in Age Group 20-79 Years (in ' 000), 2003-2006E
• Figure 4-22: Japan - Forecast for Diabetic Patients in Age Group 20-79 Years (in ' 000), 2007, 2013, 2019 & 2025
• Figure 4-23: Japan - Insulin Market (in Billion JPY), 2004-2006E & 2012F
• Figure 4-24: Japan - Share of Novo Nordisk in Insulin Market (%), 2006*
• Figure 4-25: Germany - Diabetic Patients in Age Group 20-79 Years (in ' 000), 2003-2006E
• Figure 4-26: Germany - Forecast for Diabetic Patients in Age Group 20-79 Years (in ' 000), 2007, 2013, 2019 & 2025
• Figure 4-27: Germany - Insulin Market (in Billion US$), 2005-2007E
• Figure 4-28: Pakistan - Diabetic Patients in Age Group 20-79 Years (in ' 000), 2003-2006E
• Figure 4-29: Pakistan - Forecast for Diabetic Patients in Age Group 20-79 Years (in ' 000), 2007, 2013, 2019 & 2025
• Figure 4-30: Brazil - Diabetic Patients in Age Group 20-79 Years (in ' 000), 2003-2006E
• Figure 4-31: Brazil - Forecast for Diabetic Patients in Age Group 20-79 Years (in ' 000), 2007, 2013, 2019 & 2025
• Figure 4-32: Brazil - Insulin Market (in Million US$), 2000E, 2006 & 2010E
• Figure 4-33: Mexico - Diabetic Patients in Age Group 20-79 Years (in ' 000), 2003-2006E
• Figure 4-34: Mexico - Forecast for Diabetic Patients in Age Group 20-79 Years (in ' 000), 2007, 2013, 2019 & 2025
• Figure 4-35: Egypt - Diabetic Patients in Age Group 20-79 Years (in ' 000), 2003-2006E
• Figure 4-36: Egypt - Forecast for Diabetic Patients in Age Group 20-79 Years (in ' 000), 2007, 2013, 2019 & 2025
• Figure 5-1: Global, US, Europe & Japan - Insulin Units Delivered through Pen Devices (%), 2006
• Figure 5-2: US - Insulin Pen Devices Market (in Million US$), 2003-2006E
• Figure 5-3: US - Insulin Pen Devices Market (in Million US$), 2007-2010F
• Figure 5-4: US - Insulin Units Delivered through Pen Devices (%), 1996, 2000, 2004 & 2006
• Figure 5-5: US - Volume Share of Disposable & Refillable Pen Devices (%), 2006
• Figure 5-6: Europe - Insulin Units Delivered through Pen Devices (%), 1996, 2000, 2004 & 2006
• Figure 5-7: Europe - Volume Share of Disposable & Refillable Pen Devices (%), 2006
• Figure 5-8: Japan - Insulin Units Delivered through Pen Devices (%), 1996, 2000, 2004 & 2006
• Figure 5-9: Global - Share of Key Players in Pen Devices Market (%), 2005
• Figure 5-10: Global - Insulin Pumps & Disposables Market (in Million US$), 2002-2006E
• Figure 5-11: Global - Insulin Pumps & Disposables Market (in Million US$), 2007-2009F
• Figure 5-12: Global - Share of US & Non-US Markets in Insulin Pumps & Disposables Market (%), 2002-2006E
• Figure 5-13: Global - Share of US & Non-US Markets in Insulin Pumps & Disposables Market (%), 2007-2009F
• Figure 5-14: US - Insulin Pumps & Disposables Market (in Million US$), 2002-2006E
• Figure 5-15: US - Insulin Pumps & Disposables Market (in Million US$), 2007-2009F
• Figure 5-16: US - Share of Insulin Pumps & Disposables in Market (%), 2002-2006E
• Figure 5-17: US - Share of Insulin Pumps & Disposables in Market (%), 2007-2009F
• Figure 5-18: US - Sales of Insulin Pumps (in ‘000 Units), 2002-2006E
• Figure 5-19: US - Sales of Insulin Pumps (in ‘000 Units), 2007-2009F
• Figure 5-20: US - Sales of New & Replacement Insulin Pumps (in ‘000 Units), 2002-2006E
• Figure 5-21: US - Sales of New & Replacement Insulin Pumps (in ‘000 Units), 2007-2009F
• Figure 5-22: US - Cumulative Sales of New Insulin Pumps (in ‘000 Units) 2007-2009F
• Figure 5-23: US - Cumulative Sales of New Insulin Pumps for Type 1 & Type 2 Patients (in ‘000 Units), 2002-2006E
• Figure 5-24: US - Cumulative Sales of New Insulin Pumps for Type 1 & Type 2 Patients (in ‘000 Units), 2007-2009F
• Figure 5-25: US - Cumulative Penetration of Type 1 & Type 2 Patients using Insulin Pumps (%), 2002-2006E
• Figure 5-26: US - Cumulative Penetration of Type 1 & Type 2 Patients using Insulin Pumps (%), 2007-2009F
• Figure 5-27: US - Users Discontinuing Use of Insulin Pumps (%), 2002-2006E
• Figure 5-28: US - Users Discontinuing Use of Insulin Pumps (%), 2007-2009F
• Figure 5-29: Non-US - Insulin Pumps & Disposables Market (in Million US$), 2002-2006E
• Figure 5-30: Non-US - Insulin Pumps & Disposables Market (in Million US$), 2007-2009F
• Figure 5-31: Global - Share of Key Players in Insulin Pumps Market (%), 2002-2006E
• Figure 5-32: Global - Share of Key Players in Insulin Pumps Market (%), 2007-2009F
• Figure 5-33: US - Share of Key Players in Insulin Pumps Market (%), 2002-2006E
• Figure 5-34: US - Share of Key Players in Insulin Pumps Market (%), 2007-2009F
• Figure 5-35: Europe - Share of Key Players in Insulin Pumps Market (%), 2004
• Figure 5-36: Japan - Share of Nipro in Insulin Pumps Market (%), 2005
• Figure 5-37: Global - Sales of Exubera (in Million US$), 2006*, 2007** & 2015F
• Figure 5-38: Global - Forecast for Sales of Exubera, Technosphere, Air System & Aerx-iDMS (in Million US$), 2015
• Figure 5-39: Global - Forecast for Share of Inhalable Insulin (%), 2015
• Figure 5-40: US - Insulin Syringes Market (in Million US$), 2003-2006E
• Figure 5-41: US - Share of Insulin Syringes Market (%), 2003-2006E
• Figure 5-42: US - Forecast for Insulin Syringes Market (in Million US$), 2007-2010
• Figure 5-43: US - Forecast for Share of Insulin Syringes Market (%), 2007-2010
• Figure 5-44: Global - Jet Injectors & Insulin-driven Jet Injectors Market (in Million US$), 2003-2006E
• Figure 5-45: US - Insulin-driven Jet Injectors Market (in Million US$), 2003-2006E
• Figure 5-46: US - Share of Insulin-driven Jet Injectors Market (%), 2003-2006E
• Figure 5-47: Global - Forecast for Insulin-driven Jet Injectors Market (in Million US$), 2007-2010
• Figure 5-48: US - Forecast for Insulin-driven Jet Injectors Market (in Million US$), 2007-2010
• Figure 5-49: US - Forecast for Share of Insulin-driven Jet Injectors Market (%), 2007-2010
• Figure 7-1: Global - Forecast for Number of Diabetic Patients (in Million), 2013, 2019 & 2025
• Figure 7-2: Global - Forecast for Diabetes Drugs Market (in Billion US$), 2007-2012
• Figure 7-3: Global - Forecast for Insulin Market (in Billion US$), 2007-2012
• Figure 7-4: Global - Insulin Demand (in Kg), 2006 & 2012F

• Table 2-1: Global - Top 10 Countries with Maximum Diabetic Population in Age Group 20-79 Years (in Million), 2003 & 2025F
• Table 3-1: Global - Percentage of Overweight Population by Leading Countries (2006)
• Table 3-2: Global - Percentage of Diabetic Population by Leading Countries (2003)
• Table 4-1: Global - List of Top 10 Anti-diabetic Brands, 2005
• Table 4-2: India - Diabetic Patients in Age Group 20-79 Years (in ‘000), 2003
• Table 4-3: India - Forecast for Diabetic Patients in Age Group 20-79 Years (in ‘000), 2025
• Table 4-4: China - Diabetic Patients in Age Group 20-79 Years (in ' 000), 2003
• Table 4-5: China - Forecast for Diabetic Patients in Age Group 20-79 Years (in ' 000), 2025
• Table 4-6: US - Diabetic Patients in Age Group 20-79 Years (in ' 000), 2003
• Table 4-7: US - Forecast for Diabetic Patients in Age Group 20-79 Years (in ' 000), 2025
• Table 4-8: Russia - Diabetic Patients in Age Group 20-79 Years (in ' 000), 2003
• Table 4-9: Russia - Forecast for Diabetic Patients in Age Group 20-79 Years (in ' 000), 2025
• Table 4-10: Japan - Diabetic Patients in Age Group 20-79 Years (in ' 000), 2003
• Table 4-11: Japan - Forecast for Diabetic Patients in Age Group 20-79 Years (in ' 000), 2025
• Table 4-12: Germany - Diabetic Patients in Age Group 20-79 Years (in ' 000), 2003
• Table 4-13: Germany - Forecast for Diabetic Patients in Age Group 20-79 Years (in ' 000), 2025
• Table 4-14: Pakistan - Diabetic Patients in Age Group 20-79 Years (in ' 000), 2003
• Table 4-15: Pakistan - Forecast for Diabetic Patients in Age Group 20-79 Years (in ' 000), 2025
• Table 4-16: Brazil - Diabetic Patients in Age Group 20-79 Years (in ' 000), 2003
• Table 4-17: Brazil - Forecast for Diabetic Patients in Age Group 20-79 Years (in ' 000), 2025
• Table 4-18: Mexico - Diabetic Patients in Age Group 20-79 Years (in ' 000), 2003
• Table 4-19: Mexico - Forecast for Diabetic Patients in Age Group 20-79 Years (in ' 000), 2025
• Table 4-20: Egypt - Diabetic Patients in Age Group 20-79 Years (in ' 000), 2003
• Table 4-21: Egypt - Forecast for Diabetic Patients in Age Group 20-79 Years (in ' 000), 2025
• Table 5-1: Characteristics of Various Inhalable Insulin Products
• Table 8-1: Eli Lilly & Company - Key Financials (in Million US$), 2004-2006
• Table 8-2: Novo Nordisk A/S - Key Financials (in Million US$), 2004-2006
• Table 8-3: Sanofi-Aventis - Key Financials (in Million US$), 2004-2006
• Table 8-4: Becton, Dickinson and Company - Key Financials (in Million US$), 2005-2007
• Table 8-5: Medtronic, Inc. - Key Financials (in Million US$), 2005-2007